Either TLR4 and NADPH oxidase 4 (NOX4) knock-down through lentiviral delivery of siRNA remarkably inhibited the activation of ferroptosis and relieved the symptoms of HF, suggesting TLR4-NOX4 as a potential therapeutic target for HF by inhibiting ferroptosis-mediated cell death. The gene discussed is TLR4; the disease is hydrops fetalis.